24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. is witnessing a notable upswing in market activity, currently trading at $0.803 in pre-market sessions, reflecting an increase of approximately 2.03% from the previous closing price of $0.787. With a trading volume reaching 6.81 million shares, investor interest is on the rise, suggesting momentum for further growth. Technical indicators point to a potential upward trajectory if the stock price holds above the support level of $0.787, with initial targets around $0.85. Market participants are advised to monitor trading volume and price movements to assess ongoing bullish sentiment and identify potential resistance.

In an exciting development, Hoth Therapeutics has entered into a significant patent license agreement with the U.S. Department of Veterans Affairs (VA) and Emory University. This exclusive collaboration grants Hoth rights to a pioneering patent portfolio focused on “Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions.” The technology targets critical issues related to obesity and its associated health challenges, reinforcing Hoth’s commitment to delivering transformative healthcare solutions.

Robb Knie, Chief Executive Officer of Hoth Therapeutics, expressed enthusiasm about the partnership, stating, “Our collaboration with the VA and Emory University is an extraordinary opportunity to introduce this cutting-edge technology to the market.” He emphasized that the agreement strengthens the company’s mission to develop innovative solutions for obesity and related conditions.

As part of its strategy, Hoth will manage the development, marketing, and commercialization of products derived from the licensed patents, ensuring a pathway from research to real-world application. Additionally, the company is advancing its intellectual property portfolio through a letter of intent (LOI) to acquire provisional patent protections for its lead therapeutic, HT-001, aiming to expand its influence in cancer therapeutics. Hoth Therapeutics is dedicated to transforming scientific discoveries into impactful therapeutic solutions in an evolving healthcare landscape.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.